3374 Federal Register / Vol. 70, No.
14 / Monday, January 24, 2005 / Notices
Request for Comments
In accordance with the above-cited
Paperwork Reduction Act legislation,
comments on the AHRQ information
collection proposal are requested with
regard to any of the following: (a)
Whether the proposed collection of
information is necessary for the proper
performance of functions of the Agency,
including whether the information will
have practical utility; (b) the accuracy of
the Agency’s estimate of the burden
(including hours and costs) of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and, (d) ways to minimize the
burden of the collection of information
on respondents, including the use of
automated collection techniques or
other forms of information technology.
Comments submitted in response to
this notice will be summarized and
included in the request for OMB
approval of the proposed information
collection. All comments will become a
matter of public record.
Dated: January 7, 2005.
Carolyn M. Clancy,
Director.
[FR Doc. 05–1187 Filed 1–21–05; 8:45 am]
BILLING CODE 4160–90–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Agency for Toxic Substances and
Disease Registry
[Program Announcement 05002]
Public Health Conference Grant
Program; Notice of Availability of
Funds Amendment
A notice announcing the availability
of Fiscal Year 2005 funds to award a
Grant Agreement to Support Public
Health Conference Support Grant
Agreement published in the Federal
Register on November 2, 2004, Volume
69, Number 211, pages 63541–63546.
The notice is amended as follows:
On page 63543, second column, under
III.3 Other, Special Requirements,
second bullet, delete the bullet that
reads, ‘‘Applicants who do not submit a
LOI will not be eligible to submit an
application for review or funding.’’
On page 63543, third column, under
IV.2 Content and Form of Submission,
Letter of Intent (LOI), first paragraph,
delete the fifth sentence that reads, ‘‘If
you do not submit a LOI, you will not
be allowed to submit an application.’’
VerDate jul<14>2003 18:04 Jan 21, 2005 Jkt 205001
On page 63544, second column, under
IV.3 Submission Dates and Times,
delete the fourth paragraph that reads,
‘‘Applicants who do not submit an LOI
will not be eligible to submit an
application for review or funding.’’
Dated: January 14, 2005.
William P. Nichols,
Director, Procurement and Grants Office,
Centers for Disease Control and Prevention.
[FR Doc. 05–1205 Filed 1–21–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Early Hearing Detection and
Intervention (EHDI) Tracking,
Surveillance, and Integration;
Correction
In the notice document announcing
the ‘‘Early Hearing Detection and
Intervention (EHDI) Tracking,
Surveillance, and Integration,’’ Funding
Opportunity Number: RFA 05028,
appearing on page 357 in the Federal
Register issue of Tuesday, January 4,
2005, the notice is amended as follows:
On page 357, third column under
DATES, and page 360, second column
under Section IV.3. Submission Dates
and Times: amend to reflect Letter of
Intent Deadline (LOI) Date: February 10,
2005, and Application Deadline Date:
March 14, 2005.
On page 359, second column under
Section III.3. Other: fourth bullet delete
the semicolon and the word and [; and];
delete fifth bullet ‘‘Have previously
been awarded a CDC Cooperative
Agreement for EHDI Tracking,
Surveillance, and Integration (Program
Announcements 00076, 01048, or
03055).’’
Dated: January 14, 2005.
William P. Nichols,
Director, Procurement and Grants Office,
Centers for Disease Control and Prevention
(CDC).
[FR Doc. 05–1219 Filed 1–21–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Cardiovascular and Renal Drugs
Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice.
PO 00000 Frm 00020 Fmt 4703 Sfmt 4703 E:\FR\FM\24JAN1.SGM
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Cardiovascular
and Renal Drugs Advisory Committee
(CRDAC).
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on February 24, 2005, from 8 a.m.
to 5 p.m.
Location: Food and Drug
Administration, Center for Drug
Evaluation and Research Advisory
Committee Conference Room, rm. 1066,
5630 Fishers Lane, Rockville, MD.
Contact Person: Cathy Groupe, Center
for Drug Evaluation and Research (HFD–
21), Food and Drug Administration,
5600 Fishers Lane, (for express delivery,
5630 Fishers Lane, rm. 1093) Rockville,
MD 20857, 301–827–7001, e-mail:
groupec@cder.fda.gov, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area), code
3014512533. Please call the Information
Line for up-to-date information on this
meeting.
Agenda: The committee will discuss
supplemental new drug applications
(sNDAs) S–022, S–024, and S–025 to
approved new drug application (NDA)
20–838, ATACAND (candesartan
cilexetil) Tablets (4 milligrams (mg), 8
mg, 16 mg, and 32 mg), AstraZeneca LP,
for the use in the treatment of patients
with congestive heart failure,
specifically in the following ways: (1)
S–022, reducing the risk of
cardiovascular mortality or heart failure
hospitalization when added to an
angiotensin-converting enzyme
inhibitor-containing regimen in
congestive heart failure patients with
left ventricular systolic dysfunction; (2)
S–024, reducing the risk of
cardiovascular mortality or heart failure
hospitalization in congestive heart
failure patients with left ventricular
systolic dysfunction, as a primary renin-
angiotensin-aldosterone system
modulating treatment; and (3) S–025,
reducing the frequency of
hospitalizations for heart failure in
congestive heart failure patients with
preserved left ventricular systolic
dysfunction. ATACAND is currently
approved for use in the treatment of
hypertension. The background material
will become available no later than the
day before the meeting and will be
posted on FDA’s Web site at http://
www.fda.gov/ohrms/dockets/ac/
acmenu.htm under the heading
24JAN1
 Federal Register / Vol. 70, No. 14 / Monday, January 24, 2005 / Notices
‘‘Cardiovascular and Renal Drugs
Advisory Committee.’’ (Click on the
year 2005 and scroll down to CRDAC
meetings.)
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person by February 16, 2005. Oral
presentations from the public will be
scheduled between approximately 1
p.m. and 2 p.m. Time allotted for each
presentation may be limited. Those
desiring to make formal oral
presentations should notify the contact
person before February 16, 2005, and
submit a brief statement of the general
nature of the evidence or arguments
they wish to present, the names and
addresses of proposed participants, and
an indication of the approximate time
requested to make their presentation.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Beverly
O’Neil at 301–827–7001 at least 7 days
in advance of the meeting.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: January 12, 2005.
Sheila Dearybury Walcoff,
Associate Commissioner for External
Relations.
[FR Doc. 05–1182 Filed 1–21–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
National Advisory Committee on Rural
Health and Human Services; Notice of
Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), notice is hereby given
that the following committee will
convene its forty-ninth meeting.
Name: National Advisory Committee on
Rural Health and Human Services.
Dates and Times: March 20, 2005, 1:30
p.m.–4:30 p.m., March 21, 2005, 8:30 a.m.–
4:30 p.m., March 22, 2005, 8 a.m.–10:30 a.m.
Place: Grand Hyatt, 1000 H Street, NW.,
Washington, DC 20001, Phone: 1–800–233–
1234.
VerDate jul<14>2003 18:04 Jan 21, 2005 Jkt 205001
Status: The meeting will be open to the
public.
Purpose: The National Advisory
Committee on Rural Health and Human
Services provides advice and
recommendations to the Secretary with
respect to the delivery, research,
development and administration of health
and human services in rural areas.
Agenda: Sunday afternoon, March 20, at
1:30 p.m., the Chairperson, the Honorable
David Beasley, will open the meeting and
welcome the Committee. The first session
will open with a discussion of the Committee
business and a review of the 2005 report to
the Secretary. This will be followed by an
update from the Committee Staff represented
by the following: Ms. Jennifer Riggle, Office
of Rural Health Policy; Mr. Dennis Dudley,
Agency on Aging; and Ms. Ann Barbagallo,
Administration on Children and Families.
The final session of the day will consist of
an in-depth review and adoption of the 2005
report to the Secretary. The Sunday meeting
will close at 4:30 p.m.
Monday morning, March 21, at 8:30 a.m.
the meeting will begin with the 2006 Report
Planning, led by the Honorable David
Beasley and Mr. Tom Morris, the Executive
Secretary of the Committee. The Committee
will hear presentations from Staff on each
potential 2006 topic. The Committee will
break for a joint lunch with the National
Rural Health Association Policy Institute
(lunch will be provided for the Committee
only). After lunch the Committee will hear a
panel discussion on rural health and human
services emerging issues. The Monday
session will conclude with a continued
discussion of the 2006 Workplan. The
Monday meeting will close at 4:30 p.m.
The final session will be convened
Tuesday morning, March 22, at 8 a.m. The
Committee will review the discussion of the
2006 Workplan. The meeting will conclude
with a discussion of the June and September
meetings. The meeting will be adjourned at
10:30 a.m.
FOR FURTHER INFORMATION CONTACT:
Anyone requiring information regarding
the Committee should contact Tom
Morris, M.P.A., Executive Secretary,
National Advisory Committee on Rural
Health and Human Services, Health
Resources and Services Administration,
Parklawn Building, Room 9A–55, 5600
Fishers Lane, Rockville, MD 20857,
telephone (301) 443–0835, Fax (301)
443–2803.
Persons interested in attending any
portion of the meeting should contact
Deanna Durrett, Office of Rural Health
Policy (ORHP), by telephone (301) 443–
0835, or e-mail ddurrett@hrsa.gov. The
Committee meeting agenda will be
posted on ORHP’s Web site at http://
www.ruralhealth.hrsa.gov.
Dated: January 13, 2005.
Steven A. Pelovitz,
Associate Administrator for Administration
and Financial Management.
[FR Doc. 05–1183 Filed 1–21–05; 8:45 am]
BILLING CODE 4165–15–P
PO 00000 Frm 00021 Fmt 4703 Sfmt 4703 E:\FR\FM\24JAN1.SGM
3375
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Advisory Committee on Training in
Primary Care Medicine and Dentistry;
Notice of Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Public Law 92–463), notice is hereby
given of the following meeting:
Name: Advisory Committee on Training in
Primary Care Medicine and Dentistry.
Dates and Times: February 10, 2005, 8:30
a.m.–4:30 p.m., February 11, 2005, 8 a.m.–2
p.m.
Place: DoubleTree Hotel Rockville, 1750
Rockville Pike, Rockville, Maryland 20852
Status: The meeting will be open to the
public.
Purpose: The Advisory Committee
provides advice and recommendations on a
broad range of issues dealing with programs
and activities authorized under section 747
of the Public Health Service Act as amended
by The Health Professions Education
Partnership Act of 1998, Public Law 105–
392. At this meeting the Advisory Committee
will continue to work on its fifth report
which will be submitted to Congress and to
the Secretary of the Department of Health
and Human Services in November 2005 and
which focuses on measuring outcomes of
Title VII, section 747 grant programs.
Agenda: The meeting on Thursday,
February 10, will begin with opening
comments from the Chair of the Advisory
Committee. A plenary session will follow in
which Advisory Committee members will
discuss various sections of the fifth report.
The Advisory Committee will divide into
workgroups to further develop the fifth
report. An opportunity will be provided for
public comment.
On Friday, February 11, the Advisory
Committee will meet in plenary session to
continue its work on the fifth report. An
opportunity will be provided for public
comment.
For Further Information Contact:
Anyone interested in obtaining a roster of
members or other relevant information
should write or contact Jerilyn K. Glass,
M.D., Ph.D., Division of Medicine and
Dentistry, Bureau of Health Professions,
Health Resources and Services
Administration, Room 9A–27, Parklawn
Building, 5600 Fishers Lane, Rockville,
Maryland 20857, Telephone (301) 443–6326.
The Web address for information on the
Advisory Committee is http://bhpr.hrsa.gov/
medicine-dentistry/actpcmd.
Dated: January 13, 2005.
Steven A. Pelovitz,
Associate Administrator for Administration
and Financial Management.
[FR Doc. 05–1184 Filed 1–21–05; 8:45 am]
BILLING CODE 4165–15–P
24JAN1